Advanced Search
Contact | Corporate | Help

Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Sponsors:
  • Memorial Sloan-Kettering Cancer Center
  • Sanofi-Aventis
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Stomach Neoplasms
  • Esophageal Neoplasms
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Enrollment:
44

Additional information about NCT00390416.


SourceSolution © 2008-2012